ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research...

ContraFect Corporation Announces Proposed Public Offering of Common Stock YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...

ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections Initiated expanded access program with exebacase for the...